<div id="readability-page-1"><p>In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Bristol-Myers Squibb, with a price target of <span id="expert-recommendation-target">$75.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.  </li><li>Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter </li></ul> <p>Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, Teva Pharmaceutical, and AbbVie. According to TipRanks, Amsellem has an average return of <span>11.7%</span> and a 57.52% success rate on recommended stocks. </p> <p>In addition to Piper Sandler, Bristol-Myers Squibb also received a Buy from UBS’s Michael Yee in a report issued on May 28. However, yesterday, Citi maintained a Hold rating on Bristol-Myers Squibb (NYSE: BMY).</p></div>

<p>Piper Sandler analyst David Amsellem reiterated a Buy rating on Bristol-Myers Squibb (BMY) with a $75 price target. This follows a recent Buy from UBS, while Citi maintained a Hold rating on the stock.</p>

Tip Ranks

Bristol Myers Squibb

Piper Sandler Cos

Amgen

Teva Pharmaceutical Industries

Abbvie

UBS Group AG

Citigroup

Bristol-Myers Squibb Company

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Bristol-Myers Squibb (BMY) Receives a Buy from Piper Sandler